Related Experiment Video

Updated: Sep 16, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

[Recent Advances in the Treatment of Non-small Cell Lung Cancer with Brigatinib]

Jia Yu1, Shengxiang Ren1

  • 1Department of Oncology, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200082, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|July 10, 2025
PubMed

Insights

Brigatinib, an advanced anaplastic lymphoma kinase (ALK) inhibitor, shows significant efficacy in non-small cell lung cancer (NSCLC) patients. It improves tumor response, treats brain metastases, and enhances survival for ALK-positive NSCLC.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Anaplastic lymphoma kinase (ALK) gene rearrangements are key drivers in a subset of non-small cell lung cancer (NSCLC).
  • Targeted therapies inhibiting ALK have revolutionized NSCLC treatment, leading to the development of next-generation inhibitors.
  • Brigatinib represents a significant advancement in ALK-targeted therapy for NSCLC.

Purpose of the Study:

  • To review the current advancements and future directions of Brigatinib therapy.
  • To highlight the clinical benefits of Brigatinib in ALK-positive NSCLC.
  • To discuss Brigatinib's efficacy in managing specific challenges like brain metastases.

Main Methods:

  • Literature review of clinical trials and research studies on Brigatinib.
  • Analysis of efficacy data regarding tumor response, survival, and quality of life.
  • Exploration of emerging research and potential therapeutic strategies involving Brigatinib.

Main Results:

  • Brigatinib demonstrates substantial efficacy in patients with ALK-positive NSCLC.
  • Clinical benefits include deep tumor response and effective treatment of brain metastases.
  • Improved quality of life and long-term survival are observed in patients treated with Brigatinib.

Conclusions:

  • Brigatinib is a highly effective next-generation ALK inhibitor for NSCLC.
  • It offers significant clinical advantages, including for patients with brain metastases.
  • Further research into Brigatinib's applications and optimal use is warranted.
Keywords:
Anaplastic lymphoma kinase-tyrosine kinase inhibitorsBrigatinibEfficacyLung neoplasmsNon-small cell lung cancerSafety

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
263
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K